Media
Latest News
Washington, DC: Congressman Gus Bilirakis and other Members of the Florida congressional delegation are questioning the U.S. Food and Drug Administration's (FDA) sudden decision to revoke the emergency use authorizations for two monoclonal antibody drugs. This decision cut off these treatment options for thousands of Floridians in need and forced all of the state's monoclonal antibody treatment sites to close.
Washington, DC: Representatives Gus Bilirakis and Nicole Malliotakis recently sent a stern letter to Secretary of State Antony Blinken vociferously objecting to the Administration's recent reversal of support for the Eastern Mediterranean Pipeline. By undermining the project, the Administration is undercutting three of our strongest allies in the region: Israel, Greece, and Cyprus, as well as the European Union's hopes for energy independence and economic prosperity.
Washington, DC: Today, Congressman Gus Bilirakis and a group of his colleagues co-sponsored a House Resolution condemning the heinous terrorist attack on Congregation Beth Israel in Colleyville, Texas, on January 15, 2022. This resolution acknowledges the local, state, and federal law enforcement officers who responded swiftly to Saturday's incident, and makes it clear that the United States Congress stands behind both the city of Colleyville and the entire Jewish community.
WASHINGTON, D.C. – Today, Congressman Gus Bilirakis and Senator Rick Scott sent a letter to the executives of Meta Platforms, Inc., WhatsApp, Instagram, YouTube, Twitter, Snap Inc., and TikTok requesting information about each platform's actions to stop the raging opioid crisis, which took the lives of more than 75,000 Americans over the last year.
Washington, D.C. — Earlier today, Representatives Gus Bilirakis (R-FL) and Neal Dunn (R-FL) teamed with Senators Marco Rubio (R-FL) and Rick Scott (R-FL), along with other Republican members of the Florida congressional delegation to urge U.S. Department of Health and Human Services (HHS) Secretary Xavier Becerra to reverse its burdensome allocation for monoclonal antibody drugs (mAbs) and return to a state-based model in which states and local healthcare providers can directly order mAbs from drug manufacturers.